Polycythemia Vera is a rare disease with a prevalence of approximately 22 cases per 100K people characterized by an increased number of red blood cells in the bloodstream, and affected people may also have excess white blood cells and platelets. Most Polycythemia Vera cases are not inherited and are acquired during a person’s lifetime.
Polycythemia Vera Usually diagnosed at the 60–65 years.

What Are Some Warning Signs?
Headache
Dizziness
Fatigue
Blurred vision or blind spots
Shortness of breath
Itchy skin
Spleen enlargement blood clot
Heavy bleeding
Polycythemia Vera Epidemiology Insights (2022)
The total number of Polycythemia vera prevalent cases in the 7MM was 309k
The total prevalent population of in Polycythemia vera US was 58% in 2022
The total prevalent population of in Polycythemia vera in the EU4 and UK was 32% in 2022
The total prevalent population of in Polycythemia vera in Japan was 10% in 2022
Males had the highest prevalent cases of Polycythemia vera as compared to females






asymptomatic cases < symptomatic cases in the US in 2022.
Epidemiology Segmentation in the 7MM from 2019 to 2032
The Epidemiological Segmentation of Polycythemia vera from 2019 to 2032 is segmented as:-
Total prevalent cases of Polycythemia vera
Prevalent population based on symptoms of Polycythemia vera
Gender-specific cases of Polycythemia vera
Prevalence by gene mutation of Polycythemia vera
Prevalence based on risk of Polycythemia vera
Age-specific prevalence of Polycythemia vera

Market Insight Polycythemia vera
The Market Size of Polycythemia Vera in the 7MM was valued USD 1.8 billion in the year 2022.
The US accounted for the largest market size of Polycythemia vera
Polycythemia vera Market Analysis
Polycythemia vera Market Strengths
Based on increasing sales of Jakafi, the drug is expected to be a blockbuster therapy in 2L PV patients.
Polycythemia vera Market Opportunities
Larger Opportunity for Incyte’s Itacitinib, the only JAK inhibitor in the pipeline, as Jakafi’s generic are expected to enter by 2028, thereby leading to market erosion of Jakafi.

Polycythemia vera Emerging Drugs
The emerging drugs in the Polycythemia vera market are :-
Rusfertide (PTG-300)
Bomedemstat (IMG-7289)Givinostat (ITF2357)
Sapablursen (IONIS-TMPRSS6-LRx)SLN124
PPMX-T003, and others


Key Polycythemia vera
The key companies in the Polycythemia vera market are
Protagonist Therapeutics
Imago BioSciences
Italfarmaco
Ionis Pharmaceutical
Silence Therapeutics
Perseus Proteomics, and others